These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 17724495)
41. A short report on clinical evaluation of RIX4414: highlights of world-wide development. De Vos B; Delem A; Hardt K; Bock HL; Meurice F; Innis B Vaccine; 2006 May; 24(18):3777-8. PubMed ID: 16584814 [No Abstract] [Full Text] [Related]
42. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Tregnaghi MW; Abate HJ; Valencia A; Lopez P; Da Silveira TR; Rivera L; Rivera Medina DM; Saez-Llorens X; Gonzalez Ayala SE; De León T; Van Doorn LJ; Pilar Rubio MD; Suryakiran PV; Casellas JM; Ortega-Barria E; Smolenov IV; Han HH; Pediatr Infect Dis J; 2011 Jun; 30(6):e103-8. PubMed ID: 21378594 [TBL] [Abstract][Full Text] [Related]
43. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Parashar UD; Alexander JP; Glass RI; MMWR Recomm Rep; 2006 Aug; 55(RR-12):1-13. PubMed ID: 16902398 [TBL] [Abstract][Full Text] [Related]
44. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq. Ciarlet M; Schödel F Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144 [TBL] [Abstract][Full Text] [Related]
45. RotaTeq: a new oral rotavirus vaccine. Med Lett Drugs Ther; 2006 Jul; 48(1240):61-3. PubMed ID: 16874281 [No Abstract] [Full Text] [Related]
46. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. De Vos B; Han HH; Bouckenooghe A; Debrus S; Gillard P; Ward R; Cheuvart B Pediatr Infect Dis J; 2009 Apr; 28(4):261-6. PubMed ID: 19289978 [TBL] [Abstract][Full Text] [Related]
47. Discovery of rotavirus: Implications for child health. Bishop R J Gastroenterol Hepatol; 2009 Oct; 24 Suppl 3():S81-5. PubMed ID: 19799704 [TBL] [Abstract][Full Text] [Related]
48. Rotavirus vaccines: safety, efficacy and public health impact. Gray J J Intern Med; 2011 Sep; 270(3):206-14. PubMed ID: 21668823 [TBL] [Abstract][Full Text] [Related]
49. Influence of potential protective mechanisms on the development of live rotavirus vaccines. Ward RL; Clark HF; Offit PA J Infect Dis; 2010 Sep; 202 Suppl():S72-9. PubMed ID: 20684721 [TBL] [Abstract][Full Text] [Related]
50. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. Bernstein DI; Glass RI; Rodgers G; Davidson BL; Sack DA JAMA; 1995 Apr; 273(15):1191-6. PubMed ID: 7707626 [TBL] [Abstract][Full Text] [Related]
51. The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease. Glass RI; Tate JE; Jiang B; Parashar U J Infect Dis; 2021 Sep; 224(12 Suppl 2):S331-S342. PubMed ID: 34590142 [TBL] [Abstract][Full Text] [Related]
52. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Bines JE; Danchin M; Jackson P; Handley A; Watts E; Lee KJ; West A; Cowley D; Chen MY; Barnes GL; Justice F; Buttery JP; Carlin JB; Bishop RF; Taylor B; Kirkwood CD; Lancet Infect Dis; 2015 Dec; 15(12):1389-97. PubMed ID: 26318715 [TBL] [Abstract][Full Text] [Related]
53. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants. Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138 [TBL] [Abstract][Full Text] [Related]
55. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Sow SO; Tapia M; Haidara FC; Ciarlet M; Diallo F; Kodio M; Doumbia M; Dembélé RD; Traoré O; Onwuchekwa UU; Lewis KD; Victor JC; Steele AD; Neuzil KM; Kotloff KL; Levine MM Vaccine; 2012 Apr; 30 Suppl 1():A71-8. PubMed ID: 22520140 [TBL] [Abstract][Full Text] [Related]
56. Rotavirus vaccines: new drug. Rotavirus infection: one case of severe diarrhoea prevented per 100 vaccinated infants. Prescrire Int; 2007 Feb; 16(87):3-6. PubMed ID: 17323513 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Vesikari T; Prymula R; Schuster V; Tejedor JC; Cohen R; Bouckenooghe A; Damaso S; Han HH Pediatr Infect Dis J; 2012 May; 31(5):509-13. PubMed ID: 22228235 [TBL] [Abstract][Full Text] [Related]
58. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. Bernstein DI; Sack DA; Reisinger K; Rothstein E; Ward RL J Infect Dis; 2002 Nov; 186(10):1487-9. PubMed ID: 12404166 [TBL] [Abstract][Full Text] [Related]
59. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. American Academy of Pediatrics Committee on Infectious Diseases Pediatrics; 2007 Jan; 119(1):171-82. PubMed ID: 17200286 [TBL] [Abstract][Full Text] [Related]
60. An infant with acute gastroenteritis caused by a secondary infection with a Rotarix-derived strain. Sakon N; Miyamoto R; Komano J Eur J Pediatr; 2017 Sep; 176(9):1275-1278. PubMed ID: 28733861 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]